Tacrolimus Envarsus Xr denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for tacrolimus envarsus xr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Tacrolimus Envarsus XR as Experimental

An experimental or investigational denial from Cigna typically means the plan's medical policy reviewers have determined that — under Cigna's specific coverage criteria — the evidence base for this formulation in your clinical situation does not yet meet their threshold for established clinical benefit. For Envarsus XR, this denial is most likely to appear when the indication in your chart differs from the primary FDA-approved indication, or when the claim lacks documentation tying your use to the approved label.

It is worth noting that Envarsus XR holds full FDA approval. A denial framed as "experimental" for an FDA-approved product is legally and medically distinct from a denial for a truly unapproved therapy, and insurers are required to have clinical basis for that classification. This is a strong foundation for appeal.

## Your Federal Appeal Rights

• Internal appeal: File within the window shown on your Explanation of Benefits or denial notice. Cigna must issue a decision within the regulatory timeframe for your claim type.
• External review (ACA §2719): Non-grandfathered plans must offer independent external review. You typically have approximately four months from the final internal denial to request it. An independent reviewer unaffiliated with Cigna will evaluate whether the experimental classification is clinically supported.
• ERISA §503: Employer-plan members are entitled to a full-and-fair review, including the right to receive the specific clinical rationale and any internal guidelines used to classify the therapy as experimental.
• Expedited review: Available when delay could seriously jeopardize your health — request expedited track for both internal and external review simultaneously.

## What to Gather

1. FDA approval documentation: A copy of the FDA approval for Envarsus XR and its approved indication(s). Your prescriber or pharmacist can help obtain this. 2. Diagnosis confirmation: Records establishing your diagnosis and why immunosuppression with tacrolimus is indicated. 3. Prior treatment history: Documentation of your immunosuppression history, including any tolerability or stability issues with alternative formulations. 4. Prescriber medical-necessity letter: Your transplant or treating physician should explicitly state that Envarsus XR is FDA-approved, that its use in your case falls within the approved indication, and should cite relevant transplant society guideline recommendations. 5. Cigna's experimental criteria: Request in writing the specific clinical evidence standard Cigna applied to classify this therapy as experimental, then rebut each element with published medical literature your physician can identify.

## Criteria-Mapping Structure

Obtain Cigna's coverage policy for Envarsus XR or extended-release tacrolimus from their online policy library. Map each criterion Cigna listed in the denial to a chart fact or published reference:

| Cigna Experimental Criterion | Rebuttal Evidence | |---|---| | [Criterion from Cigna policy] | [FDA label section / guideline organization reference / chart note] |

This structured rebuttal directly answers the denial rationale and is the format most likely to succeed on internal appeal — and, if needed, external review.